Search
Now showing items 11-20 of 25
Cladribine Personalised Dosing to Treat Active Multiple Sclerosis - Follow-up in 250 patients
(2021-06)
This is the accepted manuscript of an article published online:
1. ACTRIMS Forum 2021 – Poster Presentations. Multiple Sclerosis Journal. 2021;27(1_suppl):15-122. doi:10.1177/13524585211015908
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
(2020-06-08)
OBJECTIVE: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion ...
Anaesthetic management of people with multiple sclerosis.
(2023-10-11)
There is a lack of published guidelines on the management of patients with multiple sclerosis (MS) undergoing procedures that require anaesthesia and respective advice is largely based on retrospective studies or case ...
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
(2023)
BACKGROUND: Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges ...